Eugene Baranov
CEO · Founder
25+ years in stem cells, oncology, and aging biology. 30+ scientific publications.
Pre-Seed · 2026 · San Diego, CA
Resetting biological clocks.
Cellular therapy on a platform of autologous dormant pluripotent cells (DPC). Not slowing aging. Not masking it. Rewriting the program — at the level of the body's own youth signals.
01 · Thesis
Aging is not a disease.
It is a broken signal.
We don't slow it.
We don't mask it.
We rewrite the program — restoring the body's own youth signals at the cellular level.
02 · Problem
ZERO interventions
In all of human history, not a single intervention has extended the species' maximum lifespan.
$0B+
anti-aging market today
0
fundamental breakthroughs
03 · Why others fail
$5 billion deployed. Same dead-end.
-
$2B+Pharmacology
Rapamycin · Metformin · SenolyticsNetwork resilience of biology routes around point molecules. -
$1B+Allogeneic cellsImmune rejection — the host destroys the therapy.
-
$0.5B+Aged autologousCarry the patient's already-broken epigenetics.
-
$3.5BPartial reprogramming
Altos · Calico · Retro · NewLimitOncogenic risk under in-vivo pluripotency induction.
04 · Insight
Hydra doesn't age.
Jellyfish don't age.
They keep pluripotent cells active for life.
Mammals lose this — that loss is aging itself.
05 · Solution
The DPC platform — three layers.
-
I
Clear the noise
Therapeutic plasmapheresis — remove accumulated pro-aging signals from systemic circulation.
-
II
Restore the signal
Young exosomes and regulatory factors — reactivate youth signaling pathways.
-
III
Renew the source
Autologous dormant pluripotent cells — the patient's own cells, reawakened and directed.
06 · Why DPC works
The only platform without compromise.
| DPC our approach |
Allogeneic | iPSC | Partial reprog. |
|
|---|---|---|---|---|
| Autologous | ✓ | — | ✓ | ✓ |
| No immune rejection | ✓ | — | ✓ | ✓ |
| No oncogenic risk | ✓ | ✓ | — | — |
| Full epigenetic reset | ✓ | — | ✓ | ~ |
07 · Market
A category capital has already entered.
$0B
global stem-cell market by 2030
CAGR 20%+
$0B
deployed in longevity 2021–2026
Altos · Calico · Retro · NewLimit
0
people over 60 by 2050
per WHO
08 · Plan · 7 months
Four stages. Go / no-go at each.
-
Month 1
DPC isolation
Isolation and characterization of dormant pluripotent cells from autologous material.
-
Mo. 2–3
Functional validation
Confirm pluripotent potential and directed differentiation in vitro.
-
Mo. 4–5
Safety profile
Karyotyping, genetic stability, absence of tumorigenicity.
-
Mo. 6–7
Proof of Concept
Demonstrate epigenetic rejuvenation — biomarkers, methylation, transcriptome.
09 · Team
Scientists who have walked from bench to clinic.
Vadim Stepanov
CSO · Clinical Lead
Clinical lead with deep expertise in therapeutic plasmapheresis.
Gordana Olbina, Ph.D.
Head of Laboratory
ex-Intrinsic Life Sciences. CLIA / CAP standards.
Hui Ma, Ph.D.
Senior Scientist
UC San Diego · Salk Institute · Max Planck. Publications in Cell, PNAS.
10 · Ask
Pre-Seed · $100,000
- 55%Lab work and reagents
- 30%Personnel · FTE
- 10%Equipment access · cytometry, sequencing
- 5%Operations · cloud, IP, legal
11 · Contact
If we are right — this is a new category of medicine.
Join the work.
Eugene Baranov
CEO · Founder
San Diego, California